Services

Screening

An EU-OPENSCREEN screening site will take the robust, miniaturised assay together with established orthogonal and counter screens through the high throughput screening process, followed by confirmatory (dose response) and counter screening (identical assay without the target or with non-functional target), until a final list of confirmed hit compounds is established.

This process includes the following services:

  • HTS (of the entire EU-OPENSCREEN chemical collection)
  • In silico profiling, including basic chemoinformatic analysis and identification of frequent hitters and other potential false positives
  • Hit selection
  • Confirmatory screening, including orthogonal assay and IC/EC50 determination
  • Basic counter screening
  • Basic SAR based on screening data
  • QC of confirmed hits for a biochemical screen, the hit confirmation process includes testing for activity in a cell-based model.
  • Fragment based library screening
  • Virtual screening


EU-OPENSCREEN screening partner sites:

Czech Republic (CZ):

  • Palacký University Olomouc, Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine (IMTM), Dr. Marian Hajduch, Dr. Petr Dzuba,
    Site information poster
  • Institute of Molecular Genetics AS CR, v. v. i. (IMG), Dr. Petr Bartůněk,
    Site information poster

Germany (DE):

  • Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP)/MDC Berlin, Chemical Biology – Screening Unit, Dr. Jens Peter von Kries,
    Site information poster
  • Helmholtz-Zentrum für Infektionsforschung GmbH (HZI), Department of Chemical Biology (CBIO), Prof. Mark Brönstrup,
    Site information poster
  • Fraunhofer Institute for Molecular Biology and Applied Ecology IME- Department ScreeningPort, Dr. Bernhard Ellinger, Dr. Björn Windshügel, Dr. Sheraz Gul,
    Site information poster

Spain (ES):

  • FUNDACION MEDINA, Screening and target validation, Microbiology and Chemistry, Dr. Olga Genilloud, 
    Site information poster
  • Prince Felipe Research Center (CIPF), Advanced Therapies Program, Screening Platform, Dr. María J. Vicent,
    Site information poster
  • University of Santiago de Compostela, BioFarma Research Group, Prof. Mabel Loza,
    Site information poster

Finland (FI):

  • University of Helsinki, Faculty of Pharmacy, Division of Pharmaceutical Biosciences, Prof. Arto Urtti,
    Site information poster
  • Institute for Molecular Medicine Finland (FIMM), High Throughput Biomedicine (HTB) unit, Dr. Jani, Saarela
    Site information poster

Norway (NO):

  • University of Bergen, Department of Biomedicine, Faculty of Medicine and Dentistry, Prof. Aurora Martinez,
    Site information poster
  • University of Oslo, Faculty of Medicine, Biotechnology Centre of Oslo (BiO) and Centre for Molecular Medicine (NCMM), Prof. Kjetil Taskén,
    Site information poster
  • Arctic University of Norway, Faculty of Biosciences, Economics and Fisheries, Prof. Jeanette H. Andersen,
    Site information poster
  • SINTEF Materials and Chemistry, Dr. ing. Geir Klinkenberg,
    Site information poster

Poland (PL):

  • Institute of Medical Biology, Polish Academy of Sciences (IMB PAS), Screening laboratory for anti-viral and anti-bacterial compounds, Prof. Dr. Zbigniew J. Leśnikowski,
    Site information poster
  • Institute of Bioorganic Chemistry (IBCH), Polish Academy of Science, Dr. Radosław Pilarski, Dr. Jacek Kolanowski,
    Site information poster